<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03371862</url>
  </required_header>
  <id_info>
    <org_study_id>17IC3834</org_study_id>
    <nct_id>NCT03371862</nct_id>
  </id_info>
  <brief_title>Liraglutide on Decreasing Parenteral Support in Short Bowel Patients (SLIPS)</brief_title>
  <acronym>SLIPS</acronym>
  <official_title>Pilot Study of the GLP-1 Agonist, Liraglutide, on Decreasing Parenteral Support Requirements in Short Bowel Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pilot study looking at the effect on Liraglutide in the reduction of parenteral support in&#xD;
      patients with short bowel.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No participants recruited. Not able to recruit due to COVID 19.&#xD;
  </why_stopped>
  <start_date type="Actual">October 20, 2017</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Actual">August 6, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Pilot study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in parenteral support</measure>
    <time_frame>20 weeks post start of drug</time_frame>
    <description>Improvement of parenteral support on 20 weeks of Liraglutide</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in quality of life</measure>
    <time_frame>20 weeks post start of drug</time_frame>
    <description>Improvement in Euroqol EQ5-D score. Level 1: indicating no problem, Level 5: indicating extreme problems.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>20 weeks</time_frame>
    <description>Duration of response i.e. proportion of subjects who maintain reduction in weekly PN volume from baseline at week 20.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days/Nights not requiring PS</measure>
    <time_frame>20 weeks</time_frame>
    <description>Days/Nights not requiring PS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma citrulline, GLP-1, IGF-1 and PYY concentrations</measure>
    <time_frame>20 weeks</time_frame>
    <description>Change in plasma citrulline, GLP-1, IGF-1 and PYY concentrations</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Short Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Test group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide Pen Injector [Victoza]</intervention_name>
    <description>Pilot study of liraglutide in patients with short bowel.</description>
    <arm_group_label>Test group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Short bowel (≤200cm) as a result of major intestinal resection (e.g. due to injury,&#xD;
             volvulus, vascular disease, Crohn's disease).&#xD;
&#xD;
          2. Jejunostomy patients only&#xD;
&#xD;
          3. 12 continuous months of parenteral support (PS) dependency prior to enrolment.&#xD;
&#xD;
          4. PS required at least 3 times per week to meet their caloric, fluid or electrolyte&#xD;
             needs due to on-going malabsorption.&#xD;
&#xD;
          5. Stable PS for at least 4 consecutive weeks immediately prior to first dose of&#xD;
             liraglutide. Stability is described as:&#xD;
&#xD;
               1. Actual PS usage should match prescribed PS;&#xD;
&#xD;
               2. Baseline 48-hour urine output is 1-2 L/24 hours.&#xD;
&#xD;
          6. Body mass index ≥ 19.5 kg/m2.&#xD;
&#xD;
          7. Adequate hepatic and renal function:&#xD;
&#xD;
               1. Total bilirubin within the normal range;&#xD;
&#xD;
               2. Alanine aminotransferase (ALT) ≤ 2.5x upper limit of normal;&#xD;
&#xD;
               3. Serum creatinine ≤1.5x upper limit of normal.&#xD;
&#xD;
          8. Stable dosage for &gt; 4 weeks, prior to baseline evaluations, of anti-motility and&#xD;
             anti-diarrhoeal agents, H2 antagonists, proton pump inhibitors, bile sequestering&#xD;
             agents and oral rehydration solutions.&#xD;
&#xD;
          9. Female subjects must be on acceptable method of contraception for a minimum of 4 weeks&#xD;
             prior to the start of the trial; Acceptable methods of contraception would be a&#xD;
             barrier form of contraception, oral contraceptive pill, contraceptive injection or&#xD;
             implant or intrauterine implanted device.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients &lt; 18 years of age&#xD;
&#xD;
          -  Pregnancy (Female subjects who are not surgically sterile or post menopausal (defined&#xD;
             as aged 55 years or older and/or at least 2 years have elapsed since the last menses)&#xD;
             or who are not using medically acceptable methods of birth control during and for 30&#xD;
             days after the treatment period. Acceptable methods of contraception would be a&#xD;
             barrier form of contraception, oral contraceptive pill, contraceptive injection or&#xD;
             implant or intrauterine implanted device.&#xD;
&#xD;
          -  Active malignancy&#xD;
&#xD;
          -  Previous malignancy within the past 5 years&#xD;
&#xD;
          -  History of multiple endocrine neoplasia type 2 (MEN 2)&#xD;
&#xD;
          -  Personal history or family history of medullary thyroid cancer&#xD;
&#xD;
          -  Raised serum calcitonin (a biomarker for medullary thyroid cancer) at beginning of&#xD;
             trial period&#xD;
&#xD;
          -  History of cardiac failure&#xD;
&#xD;
          -  Concurrent use of diuretics&#xD;
&#xD;
          -  Previous history of pancreatitis&#xD;
&#xD;
          -  Recent use of other incretin based therapy in the previous 3 months&#xD;
&#xD;
          -  Concurrent use of octreotide&#xD;
&#xD;
          -  Type 1 or Type 2 diabetes&#xD;
&#xD;
          -  Alcohol or drug abuse in last year&#xD;
&#xD;
          -  &gt; 4 hospitalisations related to short bowel or its treatment over the previous year&#xD;
&#xD;
          -  Any hospitalisation 30 days prior to screening&#xD;
&#xD;
          -  Introduction or dose adjustment of immunosuppressant for inflammatory bowel disease&#xD;
             within 6 months, or treatment with biologics within the past 6 months (systemic&#xD;
             corticosteroids, methotrexate, cyclosporine, tacrolimus, sirolimus, MMF, infliximab,&#xD;
             adalimumab, vedolizumab)&#xD;
&#xD;
          -  BMI &lt; 19 kg/m2 or &gt; 27kg/m2 (An upper cut-off BMI of &gt; 27kg/m2 has been chosen, as in&#xD;
             these patients, there is often a desire to reduce BMI which will conflict with the&#xD;
             study design by adding another variable)&#xD;
&#xD;
          -  Scleroderma/radiation enteritis/coeliacs disease/refractory or tropical sprue&#xD;
&#xD;
          -  Liver and renal function outside the inclusion range&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Siddhartha Oke</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St Mark's Hospital</name>
      <address>
        <city>Harrow</city>
        <zip>HA1 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>October 25, 2017</study_first_submitted>
  <study_first_submitted_qc>December 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2017</study_first_posted>
  <last_update_submitted>August 12, 2020</last_update_submitted>
  <last_update_submitted_qc>August 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Liraglutide</keyword>
  <keyword>Victoza</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Short Bowel Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

